To determine if Ro has activity against human myeloid leukemia, we first tested cytotoxicity effects in MOLM13 (AML, MLL-AF9+) and K562 (CML-BC, BCR-ABL+) cell lines4,27. Here, KMT2A is linked to breast cancer.